Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04388189
Other study ID # LEAP-DB
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date October 15, 2020
Est. completion date May 30, 2023

Study information

Verified date October 2020
Source Alto Neuroscience
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.


Description:

The LEAP-DB study is an 8-week, multicenter, randomized, blinded study to evaluate the performance of EEG-based biomarkers in predicting treatment outcome. Study participants will be randomized in a 1:1 ratio to receive either duloxetine or bupropion and followed for 8 weeks.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 30, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years to 85 Years
Eligibility Inclusion Criteria: - Male or female, aged 22 or older at the time of informed consent. - Diagnosis of Major Depressive Disorder (MDD) based on the Structured Clinical Interview for DSM-5 for depression. - Moderate or severe depression on DSM-5 depression criteria items, as assessed by a score of 10 or more on the Patient Health Questionnaire (PHQ-9) - Has not taken either study medications (duloxetine, bupropion) in the current episode - Has not received electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or esketamine treatment in the current episode - Provision of personally signed and dated written informed consent prior to any study procedures - Agrees to, and is eligible for all biomarker assessments (EEG, neurocognitive testing, activity and sleep monitoring, genetic testing) - Fluent in English - Ability to complete all assessments independently - Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: - Diagnosis of bipolar disorder or a psychotic disorder based on the Structured Clinical Interview for DSM-5. - Concurrent use of antipsychotics or mood stabilizers - Use of hypnotics, anxiolytics or opiate pain medications greater than three days per week and unable to reduce use to three or fewer days per week on an as needed basis - Pregnant or breastfeeding - Severe impediment to vision, hearing, comprehension, and/or hand movement that interferes with study tasks - Active substance use that interferes with ability to consent and/or complete assessments - Any contraindication to EEG (e.g. requiring high concentration oxygen) - Employees/family of employees of clinic site - Participation in another research study that began within less than 2 months prior to the first study visit

Study Design


Intervention

Drug:
Duloxetine
FDA approved antidepressant
Bupropion
FDA approved antidepressant

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Alto Neuroscience

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score The Quick Inventory of Depressive Symptomatology (QIDS-SR) is a 16 item self-report scale that measures depressive symptoms. The QIDS assesses the severity of all DSM-V criterion items required to diagnose a major depressive episode. It asks the patient to rate each of 16 items on a scale from 0 to 3. Additionally, it states the frequency and severity of symptoms that patients should consider while responding to items in the survey. Each item in the survey asks about depressive symptoms that the patient may have experienced in the past seven days. 8 weeks
Secondary Percentage decrease in depressive symptoms on the QIDS-SR at the week 8 endpoint as a function of biomarker score Quick Inventory of Depressive Symptoms (QIDS-SR) 8 weeks
Secondary Absolute score decrease from baseline to the week 8 endpoint on the QIDS-SR as a function of biomarker score Quick Inventory of Depressive Symptoms (QIDS-SR) 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A